CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

CytoDyn is  a   biotech that has worked diligently but unsuccessfully to produce an one-time therapy, variously named Pro 140, leronlimab, and Vyrologix.

In development of this particular treatment, CytoDyn has cast its net wide and far both geographically and in terminology of prospective indications.

CytoDyn’s inventories of leronlimab are building up, whether they will actually be used is actually an open question.

While CYDY  is actually dawdling, promote opportunities for leronlimab as a combination therapy in the curing of multi-drug-resistant HIV have been closing.

I am composing my fifteenth CytoDyn (OTCQB:CYDY) report on FintechZoom to celebrate the sale made of my last several shares. My 1st CytoDyn article, “CytoDyn: What In order to Do When It’s Too Good To Be True?”, set out the following prediction:

Instead I expect it to turn into a serial disappointer. CEO Pourhassan presented such a highly promotional picture in the Uptick Newswire employment interview which I came away with a poor impression of the company.

Irony of irony, my bad impression of the business has grown steadily, however, the disappointment has not been financial. 2 many years ago CytoDyn was trading <$1.00. On 2/19/20 as I write, it trades during $5.26; the closing transaction of mine was on 2/11/21 > $6.00.

What manner of stock  is this that delivers a > 6 bagger yet still disappoints? Therein sits the story; allow me to explain.

CytoDyn acquired its much-storied treatment (which I shall refer to as leronlimab) returned throughout 2012, announced as follows:

CytoDyn Inc…. has finished the acquisition of Pro 140, an experimental humanized monoclonal antibody (MAB) targeting the CCR5 receptor of the treatment and prevention of HIV, from Progenics Pharmaceuticals, Inc. of Tarrytown, NY. Pro 140 is a late Stage II clinical development mAb with demonstrated anti-viral activity in HIV- infected subjects. Today’s payment of $3.5 huge number of transfers ownership of the expertise and connected intellectual property from Progenics to CytoDyn, and also roughly 25 million mg of majority drug substance…. milestone payments after commencement of a phase III clinical trial ($1.5 million) and the very first new drug program endorsement ($5 million), as well as royalty payments of 5 % of net sales upon commercialization.

Since that time, CytoDyn’s guiding nous, Nader Pourhassan [NP] has made this inauspicious acquisition into a springboard for CytoDyn to acquire a market cap > $3.5 billion. It’s done so in premium reliance on leronlimab.

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

 

Instead of having a pipeline with many indications and multiple therapies, it’s this individual therapies and a “broad pipeline of indications” because it puts it. I call some pipelines, “pipedots.” In CytoDyn’s situation it touts the leronlimab of its as a likely advantageous therapy of dozens of indications.

The opening banner of its on the site of its (below) shows an energetic organization with diverse interests albeit focused on leronlimab, several disease types, multiple delivering presentations in addition to multiple publications.

Can all this be smoke cigarettes and mirrors? That is a question I’ve been asking myself from the very beginning of the interest of mine in this particular organization. Judging by way of the multiples of thousands of several comments on listings accessible via Seeking Alpha’s CytoDyn Summary page, I am a lot from alone in this particular question.

CytoDyn is a traditional battleground, or possibly some may say cult stock. Its adherents are fiercely shielding of its prospects, quick to label some bad opinions as scurrilous short mongering.

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News